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Introduction: Approximately 1% to 4% of NSCLC tumors
harbor erb-b2 receptor tyrosine kinase 2 (ERBB2) mutation;
there is no approved targeted treatment for this subgroup.
Methods: Patients with stage IV NSCLC that progressed after
clinical beneﬁt on erlotinib/geﬁtinib and/or had activating
EGFR or ERBB2 mutations, had exhausted other treatments,*Corresponding author.
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50 mg/d on a compassionate basis within routine clinical
practice. Efﬁcacy and safety were retrospectively assessed in
the subgroup with ERBB2 mutation-positive NSCLC.
Results: Twenty-eight heavily pretreated patients in the
named patient use program had a documented ERBB2
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any reason) was 2.9 months; eight patients (29%) had TTF
greater than 1 year. Objective response rate was 19% (3 of
16 patients with response data achieved partial response)
and disease control rate (DCR) was 69% (11 of 16). Among
12 patients for whom type of ERBB2 mutation was speci-
ﬁed, 10 had a p.A775_G776insYVMA insertion in exon 20,
four of whom (40%) remained on afatinib for more than 1
year. This subgroup had median TTF of 9.6 months, objec-
tive response rate of 33% (two of six), and disease control
rate of 100% (six of six).
Conclusions: This analysis of patients treated in clinical
practice provides further evidence of the activity of afatinib
in ERBB2 mutation-positive NSCLC, and suggests that
identiﬁcation of speciﬁc subgroups with certain mutations,
such as p.A775_G776ins/YVMA insertion in exon 20, could
help optimize outcomes with ErbB2-targeted treatment.
 2018 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Driven by the identiﬁcation of speciﬁc genomic aber-
rations that underlie oncogenic molecular abnormalities,
targeted therapy has signiﬁcantly enhanced outcomes for
patients with NSCLC carrying activating mutations in the
EGFR gene, or translocations in the ALK receptor tyrosine
kinase (ALK) gene or ROS1.1,2 Recently, the ﬁrst targeted
treatment was approved for NSCLC harboring the BRAF
V600E mutation.3 However, several other oncogenic
drivers have been identiﬁed in NSCLC that do not yet have
approved targeted treatments; these include mutations in
KRAS, MET proto-oncogene receptor tyrosine kinase
(MET), ret proto-oncogene (RET), phosphatidylinositol-
4,5-biphosphate 3-kinase catalytic subunit alpha
(PIK3CA), and erb-b2 receptor tyrosine kinase 2 (HER2)
genes.1,2
Erb-b2 receptor tyrosine kinase 2 (ErbB2 [HER2]) is
a member of the ErbB family of tyrosine kinases, which
also includes EGFR (ErbB1), ErbB3, and ErbB4.4
Approximately 1% to 4% of NSCLC tumors harbor mu-
tations in the ERBB2 gene, and in EGFR/KRAS/ALK-
negative adenocarcinoma specimens, the frequency of
ERBB2 mutations was found to be 6%.5,6 In adenocarci-
noma, the occurrence of ERBB2 mutations appears to be
almost mutually exclusive to other oncogenic drivers, and
although such mutations were initially thought to occur
predominantly in this type of NSCLC, they have more
recently been observed in squamous cell carcinoma of the
lung.5,7,8 ERBB2 mutations are more commonly found inwomen and never-smokers than in men and former- or
current-smokers, but their prognostic implication is
unknown.9 There is increasing evidence that the use of anti-
ErbB2 agents (such as afatinib, dacomitinib, neratinib,
trastuzumab, and the antibody-drug conjugate trastuzumab
emtansine [T-DM1]) may elicit objective responses in
ERBB2 mutation–positive NSCLC.9-15 In addition, the pan-
ErbB tyrosine kinase inhibitor (TKI) poziotinib is
currently being investigated in a phase II clinical trial of
patients with advanced NSCLC, including those with inser-
tion mutations in exon 20 of ERBB2 (clinical trials no.
NCT03318939).
Afatinib is a selective inhibitor of the ErbB protein
family, which irreversibly blocks signaling of all homo-
dimers and heterodimers formed by these proteins.16,17
Having been approved in the United States and European
Union in 2013 for the treatment of EGFR mutation–
positive NSCLC (and subsequently in several other re-
gions), afatinib has more recently been approved for the
treatment of metastatic squamous NSCLC that has pro-
gressed after platinum-based chemotherapy. Initial re-
sults for the treatment of ERBB2 mutation–positive
NSCLC with afatinib have been encouraging, with objective
response or disease control observed in two case series.7,18
In addition, in a recent independent analysis presented
while this manuscript was in preparation, among 27 pa-
tients with metastatic ERBB2 mutation–positive NSCLC
treated with afatinib, the objective response rate (ORR) was
15%, with partial responses (PRs) lasting 5 to 10 months.19
Similarly, of 13 pretreated patients with ERBB2 mutation–
positive NSCLC who were enrolled in the phase II NICHE
trial, 1 (8%) achieved a PR and 7 (54%) achieved disease
control after 12 weeks of afatinib treatment.20 These ﬁnd-
ings, although modest and limited by low patient numbers,
conﬁrm that afatinib has clinical activity in some patients
with ERBB2 mutation–positive NSCLC.
A large pool of data is available for heavily pretreated
patients who received afatinib under a named patient use
(NPU) program. The program was initiated after the results
of the phase IIb/III LUX-Lung 1 trial were reported; in LUX-
Lung 1, afatinib (50 mg/d) improved progression-free
survival and ORR versus placebo in patients with
advanced NSCLC who had failed previous treatment with
the EGFR TKIs erlotinib or geﬁtinib and at least one line of
chemotherapy.21 Under the NPU program, afatinib was
made available on a compassionate use basis to patients
with no remaining established treatment option who were
ineligible for participation in afatinib trials; this included
patients with activating EGFR or ERBB2 mutations, with or
without a history of failed erlotinib or geﬁtinib treatment.
The afatinib NPU program is therefore a global source of
real-world data. Between May 2010 and January 2016,
more than 5600 patients with NSCLC received afatinib
under the NPU program, and almost 4000 patients were
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safety of afatinib in this setting; among those for whom
response data were available, 23.4% achieved an objective
response.22 Here, we report treatment outcomes for the
subset of patients with ERBB2 mutation–positive NSCLC
who were treated as part of the NPU program.
Materials and Methods
Patient Enrollment
Patients were eligible to enroll in the afatinib NPU
program if they had pathologically conﬁrmed stage IV
adenocarcinoma of the lung; had progressed after clinical
beneﬁt on erlotinib or geﬁtinib (“clinical beneﬁt” being
deﬁned as stable disease [SD] for at least 6 months, or a
complete response [CR] or PR) and/or had an activating
mutation in EGFR or ERBB2; had exhausted all other
treatment options (chemotherapy-naïve patients were
eligible if they had been deemed unﬁt for chemotherapy);
and were deemed ineligible to participate in an actively
recruiting afatinib trial.
The NPU program procedures (including enrollment
criteria and treatment details) were adapted locally and
approved in each region according to local regulations.
Written informed consent was obtained from each patient
before participation. Enrollment into the NPU program was
stopped in each country once afatinib (GIOTRIF, Boeh-
ringer Ingelheim Pharma GmbH & Co., KG, Ingelheim am
Rhein, Germany) became available on the market; enroll-
ment had ceased worldwide by January 2016.
Afatinib Treatment
The recommended starting dose for afatinib was 50
mg once daily, as in the LUX-Lung 1 trial.21 Lower starting
doses of 40 mg or 30 mg once daily were allowed if
deemed necessary by the treating physician. Dose modi-
ﬁcations were permitted based on tolerability (10-mg
steps; maximum dose of 50 mg/d; minimum dose of 30
mg/d). Combination treatment with other anticancer
therapieswas allowed if deemed necessary by the treating
physician and in accordance with local regulations.
Data Reporting
The purpose of the NPU program was to provide early
access to afatinib for patients with no other treatment
option, while also generating additional safety information
on afatinib. Participating physicians were requested to
report all serious adverse events (AEs), AEs leading to
afatinib dose reduction or discontinuation, and AEs
assessed as causally related to afatinib. Standard serious
AE forms and reporting procedures were used to record
safety data, and local regulations on safety reporting had to
be followed. Additional data, provided as anonymized
datasets, included age, sex, EGFR and ERBB2 mutationstatus and the nature of the speciﬁc mutations, disease
stage, prior therapies, and comorbidities. Some datasets
relating to patient characteristics and efﬁcacy outcomes
were incomplete because they were collected via request
forms and, whenever possible, follow-up forms were been
completed after discontinuation of afatinib. In some coun-
tries, local restrictions did not allow collection of patient
data, or precluded or limited the use of such data in a
publication.
ERBB2 Mutation-Positive Subgroup Analyses
Among patients for whom genotype information was
available, those with an activating ERBB2 mutation were
included in these retrospective analyses. In accordance
with the inclusion criteria, these patients were not
required to have received prior erlotinib or geﬁtinib.
Outcomes (as of April 2017) were evaluated for patients
with any ERBB2 mutation (the overall group), and ac-
cording to ERBB2 mutation type.
Time to treatment failure (TTF) was deﬁned as the
time from the start of afatinib treatment to the date
afatinib was discontinued for any reason (including
switching to another drug, death, or end date of available
data, whichever occurred ﬁrst). TTF was calculated in
months by dividing the number of days from start to
discontinuation of treatment by 30.417.
The ORR was calculated as the sum of patients with a
recorded CR or PR, as a proportion of the total number of
patients with available response data (those with CR, PR,
SD, progressive disease [PD], or mixed response). Dis-
ease control rate (DCR) was calculated as the sum of
patients categorized as PR, CR, and SD, as a proportion of
all patients with available response data (PR þ CR þ
SD þ PD þ mixed response). There was no independent
radiological veriﬁcation of responses, SD, or PD, so all
such response assessments were made by each individ-
ual investigator at their discretion as appropriate for a
real-world setting. Also, as in a real-world setting, scan
frequency and scan methodology were not mandated but
left to the discretion of the investigator.
Results
Patient Characteristics
Of 5650 patients with NSCLC from 49 countries
enrolled in the NPU program, 3966 patients from 41
countries were included in the overall analysis.22 A total
of 28 patients were documented as having ERBB2
mutation–positive NSCLC (16 patients with ERBB2 mu-
tations were identiﬁed in the original analysis of the
overall NPU program population22; an additional 12
patients have since been identiﬁed and were included in
the present analysis). These patients were enrolled in
Europe (8 in Switzerland, 2 in Spain, 1 each in Belgium,
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patients), Israel (2 patients), and Argentina (1 patient).
Characteristics of the ERBB2 mutation–positive patients
in the NPU program are summarized in Table 1; the
median age was 55 years (range: 39 to 93 years), 16
patients (57%) were female, and all had adenocarcinoma
histology.
Treatment history was recorded for all 28 patients.
Overall, this was a heavily pretreated population;
most patients had received at least one prior systemic
therapy (n ¼ 26; 93%), and 16 (57%) had received
three or more prior systemic therapies (Table 1). Ten
patients (36%) had received ﬁrst-generation EGFR
TKIs (erlotinib and/or geﬁtinib in any treatment line),
with only one having a concurrent EGFR mutation (an
exon 19 deletion). Seven patients (25%) had received
previous anti-ErbB2 treatment, four with trastuzumab
only, and three with both trastuzumab and lapatinib.
Treatment with afatinib was initiated at 50 mg once
daily in 11 patients (39%) and 40 mg once daily in 17
patients (61%) (Table 1).ERBB2 Mutation Type
Information on the speciﬁc ERBB2 mutation type was
available for 12 patients; all mutations were in exon 20.
Among these 12 patients, the most frequently reported
ERBB2 mutation, occurring in 10 patients (83%), was a
p.A775_G776insYVMA insertion in exon 20 (Fig. 1).19 This
insertion occurs at amino acids 776–779 and may alter-
natively be referred to as 2325/YVMA, Y772-A775dup,
p.A771-M774dup, ErbB2 G776-YVMA, and ErbB2YVMA.4Table 1. Characteristics of Patients With Conﬁrmed ERBB2
Mutation-Positive NSCLC in the Afatinib NPU Program
(N ¼ 28)
Age, y; median (range) 55 (39–93)
Gender, female/male 16 (57) / 12 (43)
Prior systemic treatment
No. of lines
0 2 (7)
1 6 (21)
2 4 (14)
3 8 (29)
4 6 (21)
‡5 2 (7)
Prior ﬁrst-generation EGFR TKIa 10 (36)
Prior anti-ErbB2 treatment 7 (25)
Trastuzumab only 4 (14)
Trastuzumab and lapatinib 3 (11)
Afatinib starting dose
40 mg 17 (61)
50 mg 11 (39)
Values are n (%) unless otherwise stated.
aErlotinib/geﬁtinib in any line.
ErbB2, erb-b2 receptor tyrosine kinase 2; NPU, named patient use;
TKI, tyrosine kinase inhibitor.The other reported mutation was the M774 duplication,
which occurred in two patients (17%) (Fig. 1).Efﬁcacy
Overall ERBB2 mutation–positive group. Median TTF
in all patients with any ERBB2 mutation (N ¼ 28) was
2.9 months. Eight patients (29%) remained on afatinib
for more than 1 year (Table 2). Tumor response data
were available for 16 patients (57%). In those patients,
the ORR was 19% (three patients achieved PR) and the
DCR was 69% (eight patients with SD plus the three
patients with PR) (Table 2).
Efﬁcacy by ERBB2 mutation type. In the subgroup
analysis conducted according to ERBB2 mutation type,
patients with the p.A775_G776insYVMA insertion muta-
tion (n ¼ 10; the most common type of ERBB2 mutation
in this study population) had a median TTF of 9.6
months, and four patients (40%) remained on afatinib
for more than 1 year. Tumor response data were avail-
able for six patients (60%) with the p.A775_G776in-
sYVMA insertion; in those patients, the ORR was 33%
(two patients achieved a PR; see patient cases 1 and 2,
below) and the DCR was 100% (four patients with SD
plus the two patients with a PR) (Table 2).
Neither of the two patients with other speciﬁed
ERBB2 mutations (both duplication mutations of M774)
remained on afatinib for more than a year; the median
TTF was 1.9 months. Response data were unavailable for
both of these patients, meaning that the ORR and DCR
could not be calculated (Table 2).Examples of Patients Who Derived Clinical
Beneﬁt From Afatinib
A Taiwanese patient with a p.A775_G776insYVMA
insertion in exon 20 who achieved PR on afatinib.
This patient was a 67-year-old male ex-smoker from
Taiwan with stage IV lung adenocarcinoma, wild-type for
EGFR and ALK, with a ERBB2 mutation of p.A775_G776in-
sYVMA insertion in exon 20. He had received ﬁrst-line
chemotherapy with cisplatin/pemetrexed; following fail-
ure of ﬁrst-line chemotherapy, afatinib was then initiated at
40 mg upon entering the NPU program. He achieved a PR
due to afatinib monotherapy and remained on afatinib
monotherapy for 236 days before disease progression was
detected (7.8 months’ progression-free survival on afatinib
monotherapy). Following progression, he was maintained
on afatinib, having experienced clear beneﬁt (PR [Fig. 2]),
with the addition of other anticancer agents in an attempt to
produce a greater degree of response through combination
therapy. He received paclitaxel plus afatinib for 172 days.
Paclitaxel was then discontinued and gemcitabine initiated
while continuing afatinib; only one dose of gemcitabine was
Figure 1. ERBB2 mutation types identiﬁed in patients
participating in the NPU program.
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quently received afatinib monotherapy. He remained on
afatinib for a total of 508 days (including all periods of
monotherapy and combination therapy), constituting a TTF
of 16.7 months. Figure 2 shows computed tomography
scans at baseline (Fig. 2A, after failing ﬁrst-line chemo-
therapy and before afatinib monotherapy) and after 6
weeks of afatinib monotreatment (Fig. 2B), and shows the
PR observed during afatinib monotreatment.
A European patient with a p.A775_G776insYVMA
insertion in exon 20 who achieved PR on afatinib.
This patient was a 60-year-old female with stage IV
adenocarcinoma of both lungs; ERBB2 genotyping
showed duplication of A771-M774 in exon 20, which
was later identiﬁed as being synonymous to the
p.A775_G776insYVMA insertion in exon 20. Before
entering the NPU program, the patient had received fourTable 2. Time to Treatment Failure and Tumor Responses in ER
Program
All ERBB2
Mutation-Positive
Patients
n (%) 28 (100)
TTF
Median TTF, months 2.9
TTF > 1 year 8 (29)
Tumor responses
Patients with response
data available
16 (57)
ORRa 3 (19)
DCRb 11 (69)
PR 3 (19)
SD 8 (50)
Values are n (%) unless otherwise stated.
aORR ¼ proportion of patients with CR or PR.
bDCR ¼ proportion of patients with CR, PR, or SD.
cND ¼ not determined as no response assessments were available.
CR, complete response; DCR, disease control rate; ND, not determined; ERBB2,
response rate; PR, partial response; SD, stable disease; TTF, time to treatmentcycles of chemotherapy with cisplatin plus gemcitabine,
followed by ﬁve cycles of chemotherapy with peme-
trexed plus carboplatin, and then erlotinib for 2 months.
Afatinib was initiated at 40 mg, as fourth-line systemic
therapy, upon entering the NPU program, and a PR was
achieved. The patient remained on afatinib monotherapy
for 360 days (TTF 11.8 months). Figure 3 shows
positron-emission tomography scans taken before initi-
ation of afatinib and after w3 months of treatment,
conﬁrming the PR and showing the reduced activity of
metastases after treatment.
Safety
The most common AEs reported to us were diarrhea/
gastrointestinal toxicity and skin disorders, which were
reported in 10 and eight patients, respectively. Reported
AEs (excluding disease progression, metastases, and
death unrelated to afatinib and due to disease progres-
sion) are presented in Table 3.
Discussion
Real-world data on the use of afatinib were available
from the NPU program for 28 heavily pretreated patients
with documented ERBB2 mutation–positive NSCLC. Me-
dian TTF for these patients was 2.9 months, and 29%
remained on afatinib treatment for more than 1 year. Of
the 16 patients for whom tumor response data were
available, 19% had an objective response and 69%
achieved disease control. There were no unexpected
safety ﬁndings.
According to the literature, most ERBB2 mutations
are located in exon 20, which encodes part of the kinaseBB2 Mutation-Positive Patients Receiving Afatinib in the NPU
Patients With
p.A775_G776insYVMA
in Exon 20
Patients With
M774dup in
Exon 20
10 (36) 2 (7)
9.6 1.9
4 (40) 0 (0)
6 (60) 0 (0)
2 (33) NDc
6 (100) NDc
2 (33) NDc
4 (67) NDc
erb-b2 receptor tyrosine kinase 2; NPU, named patient use; ORR, objective
failure.
Figure 2. Computed tomography scans at baseline (A) and after 6 weeks of afatinib treatment (B) in a Taiwanese patient with
a p.A775_G776insYVMA insertion in exon 20 who achieved a PR.
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to 4% in NSCLC.4,6,23,24 In the current analysis, ERBB2
mutation type was speciﬁed for 12 patients; all muta-
tions were in exon 20, and the p.A775_G776insYVMA
insertion was the most common, occurring in 10 patients
(83%). Two patients (17%) had another speciﬁed mu-
tation, the M774 duplication mutation in exon 20. These
ﬁndings are consistent with a previous report based on
11 patients with ERBB2 mutation–positive NSCLC, in
which all ERBB2 mutations were insertions or duplica-
tions in exon 20, with YVMA insertions being the most
common, occurring in 6 patients (55%).4 In the current
analysis, patients with a p.A775_G776insYVMA insertion
in exon 20 (n ¼ 10) appeared to derive the greatest
beneﬁt from afatinib treatment (median TTF 9.6 months,
compared with 1.9 months in patients with the M774
duplication mutation), although inferences are limited by
the small sample size as well as the absence of data for
patients with mutations other than p.A775_G776in-
sYVMA insertion or M774 duplication in exon 20.Figure 3. Positron-emission tomography scans taken (A) before
a European patient with a p.A775_G776insYVMA insertion in exThe ﬁndings of this analysis are consistent with
previous observations in patients with ERBB2 mutation–
positive NSCLC who received afatinib within a clinical
trial setting. For example, in a recent analysis of data
from 27 patients with metastatic ERBB2 mutation–
positive lung cancer who participated in an interna-
tional, multicenter clinical trial between 2009 and 2016,
the ORR was 15% (four PRs), compared with 19% in the
current analysis.19 YVMA insertion in exon 20 was the
most common ERBB2 mutation type in the clinical trial
population (59%), and the three patients who achieved
the longest lasting PRs (5 to 10 months) had this mu-
tation.19 In the NICHE trial, a single-arm phase II study of
afatinib in pretreated patients with advanced NSCLC
harboring ERBB2 mutations in exon 20 (n ¼ 13), 7 pa-
tients (54%) achieved disease control at 12 weeks.20
Although lack of activity in the other 6 patients meant
that the pre-speciﬁed criteria for proceeding to further
clinical testing were not met, descriptive molecular
analysis suggested that prolonged disease stabilizationinitiation of afatinib and (B) afterw3 months of treatment in
on 20 who achieved a PR.
Table 3. Adverse Events of Any Grade Reported in ERBB2
Mutation-Positive Patients Receiving Afatinib in the NPU
Program (N ¼ 28)
Event n
Diarrhea/gastrointestinal toxicity 10
Skin disordersa 8
Stomatitis/mucositis/mouth ulceration 4
Respiratory disordersb 3
Paronychia 2
Nausea/vomiting 2
Depressed consciousness 1
Septic shock 1
Leukocytosis 1
Paralysis 1
Excludes disease progression, metastases, and deaths unrelated to afatinib
and due to disease progression.
aSkin disorders ¼ acne, dermatitis, dermatosis, pruritus, rash, skin toxicity.
bRespiratory disorders ¼ Adult Respiratory Distress Syndrome, dyspnea, lung
infection, respiratory failure, respiratory insufﬁciency.
NPU, named patient use; ERBB2, erb-b2 receptor kinase 2.
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Therefore, despite the challenges of evaluating larger
cohorts of patients with rarer ERBB2 mutations, there is
accumulating evidence that the presence of YVMA in-
sertions in exon 20 identiﬁes a subgroup of patients with
ERBB2 mutation–positive NSCLC for whom afatinib may
be a treatment option.
Oncogenic activation of ErbB2 may result from pro-
tein overexpression, gene copy number gain (due to gene
ampliﬁcation or chromosome 17 polysomy), and gene
mutations that lead to molecular alterations in the ErbB2
receptor; limited emerging data suggest that ERBB2 gene
mutations may be more relevant in lung carcinogenesis
than ERBB2 overexpression or ampliﬁcation.25 Conse-
quently, to optimize outcomes with ErbB2-targeted
therapies in NSCLC, it may be necessary to deﬁne the
treatment population more precisely. The distinction
between ERBB2 mutation and ERBB2 ampliﬁcation is
fundamental because these appear to be mutually
exclusive forms of ERBB2 alteration that deﬁne distinct
clinical entities and represent different therapeutic
targets.26 For example, in a phase II study of the irre-
versible pan-ErbB TKI dacomitinib in patients with
ERBB2-mutant or ampliﬁed lung adenocarcinomas, PRs
(lasting 3þ, 11, and 14 months) were seen in 12% of
patients with ERBB2 exon 20 mutations, but not in pa-
tients with ERBB2 ampliﬁcations.13 Further research is
required to better understand the biology of the exon 20
YVMA mutation, as well as that of rare ERBB2 mutations,
and to further explore ErbB2-related biomarkers that
may help to deﬁne patient groups and optimize identi-
ﬁcation of patients most likely to respond to different
forms of ErbB2-targeted therapy.
The importance of precisely deﬁning oncogenic driver
ERBB2 alterations (overexpression or ampliﬁcation, aswell as nonsynonymous ERBB2 mutations) is further
illustrated by the limited efﬁcacy of established anti-
ErbB2 therapies in NSCLC, despite their proven efﬁcacy
in ERBB2-positive breast cancer. For example, studies of
trastuzumab in ERBB2-positive NSCLC have yielded
disappointing results.27-29 Potential beneﬁt was only
observed in a small subgroup of patients whose tumors
expressed high levels of ErbB2 (immunohistochemistry
level 3þ) or who had ERBB2 ampliﬁcation detected by
ﬂuorescence in situ hybridization.27,28 By contrast, in a
case study of a patient with an EGFR exon 21 mutation
and a ERBB2 exon 20 mutation, treatment with trastu-
zumab and paclitaxel elicited a PR.11 In a recent phase II
study of T-DM1 in ErbB2-overexpressing NSCLC, objec-
tive response was only seen in immunohistochemistry
level 3þ patients (ORR 20%).30 In other phase II studies,
T-DM1 was active in patients with ERBB2 mutation–
positive NSCLC with an ORR of 44% (8 of 18 patients)
in one study and an ORR of 14% (one of seven patients) in
another study. 14,31
The safety proﬁle of afatinib has been well estab-
lished, with diarrhea, rash, and stomatitis being among
the most common side effects.21,32 Cardiotoxicity is a
potential safety concern for all agents targeting ErbB2
because ErbB2 is expressed in the heart and is thought
to play a role in normal cardiac function.33 Heart failure
and increased risk of cardiac dysfunction have been re-
ported as AEs in patients treated with trastuzumab.34,35
However, there is no evidence of cardiac dysfunction
from afatinib clinical trials to date, and there were no
heart failure AEs reported in patients with ERBB2
mutation–positive NSCLC treated with afatinib in this
NPU program.36
The NPU program provides a large pool of patients
who have received afatinib in “real life” conditions in
clinical practice. However, missing information is an
inherent limitation in this type of analysis. It is likely that
the analysis did not include all patients harboring ERBB2
mutations, given that genotyping information was not
available for all patients; indeed, the frequency of ERBB2
mutations (28 of 3966 [0.7%]) was slightly lower than
the 1% to 4% range reported previously.4,5 Other
missing information included ERBB2 mutation type for
16 patients (57%) identiﬁed as having ERBB2 mutation–
positive NSCLC, tumor response data for 12 patients
(43%), and details of the number of patients who
received other anticancer therapies in combination with
afatinib. AEs may have been under-reported in this real-
world setting compared to clinical trials. Another limi-
tation was that there was no independent, central
radiological conﬁrmation of reported responses or dis-
ease progression. Survival data were not available for
the ERBB2 mutation–positive patient group; however,
interpretation of survival data would be confounded by
1904 Peters et al Journal of Thoracic Oncology Vol. 13 No. 12the high number of prior therapies received by many
patients, and the large variability in the treatment line in
which patients received afatinib.
Despite the limitations of this small, retrospective
analysis, these data show that afatinib provides clinical
beneﬁt for patients with ERBB2 mutation–positive
NSCLC, in particular those harboring the most common
ERBB2 mutation found in lung adenocarcinomas, the
p.A775_G776insYVMA insertion in exon 20. This may
suggest that, in addition to those with sensitizing EGFR
mutations, a broader group of patients could beneﬁt
from targeted treatment with afatinib. Prospective
evaluation of afatinib in ERBB2 mutation–positive NSCLC
patients is therefore warranted, and one phase II study is
currently recruiting participants (clinical trial no.
NCT02597946).
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